ASX gains three American Century-backed ETFs

The Australian Securities Exchange’s (ASX’s) AQUA market is now home to three exchange traded funds (ETFs) from American Century Investments’ venture, Avantis Investors, after they were pulled from the Cboe Australia exchange.
The Avantis Small Cap Value Active ETF (AVSV), Avantis Global Equity Active ETF (AVNG) and Avantis Emerging Markets Equity Active ETF (AVTE) were made available for trading yesterday, after they marked Avantis’ official entry into the Australian market by listing on the Cboe exchange last year.
“Trading on the ASX underscores our commitment to providing low-cost, value-added solutions that seek to empower financial professionals in Australia to create value for their clients,” Eduardo Repetto, Avantis Investors’ CIO on behalf of American Century, said.
“Since launching these dual access ETFs in September of last year, our conversations with advisers have been energising. We focus on understanding our clients very well so we can serve them with investment solutions that consider their needs.
“I believe this mentality has contributed to the broad adoption of our strategies and helped us become the 4th largest active ETF issuer in the world.”
First established in 2019 with the backing of American Century Investments, Avantis Investors leverages its expertise in indexing solutions combined with the benefits of diversification to consistently seek outperformance.
A statement from American Century also confirmed that investments with Avantis will support the work of its partner, the US-based Stowers Institute for Medical Research, which has already benefitted from over $2 billion from American Century dividends since 2000.









Gotta love our useless regulator dastardly duo acting like they’re making a big difference. Attacking the small guys again, this…
Once good - correct. Now? You have to wonder. Zurich talks a big game about claims, but according to the…
We are now seeing cohorts of policyholders being singled out, not because of broad claims deterioration across an entire product,…
Not wanting to excuse this particular instance, but no-one ever makes "wins" against an insurer. The insurer is not a…
Zurich would have to be the most prolific of the price gougers, for a once good company they are bottom…